biostudies-literatureEtrych TCharles UniversityCzech Health Research CouncilCzech Science Foundation626https://www.ebi.ac.uk/biostudies/studies/S-EPMC8833783biostudies-literatureUnknown14(3)Malignant lymphomas represent the most common type of hematologic malignancies. The first clinically approved TDD modalities in lymphoma patients were anti-CD20 radioimmunoconjugates (RIT) 131I-tositumomab and 90Y-ibritumomab-tiuxetan. The later clinical success of the first approved antibody-drug conjugate (ADC) for the treatment of lymphomas, anti-CD30 brentuximab vedotin, paved the path for the preclinical development and clinical testing of several other ADCs, including polatuzumab vedotin and loncastuximab tesirine. Other modalities of TDD are based on new formulations of "old" cytostatic agents and their passive trapping in the lymphoma tissue by means of the enhanced permeability and retention (EPR) effect. Currently, the diagnostic and restaging procedures in aggressive lymphomas aCancersTargeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas.PMC8833783Center of Excellence UNCE/MED/016AZV NU21-03-00386GACR19-01417SLambert LZogala DRenesova NKlener PEtrych TBraunova AfalseTargeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas.Malignant lymphomas represent the most common type of hematologic malignancies. The first clinically approved TDD modalities in lymphoma patients were anti-CD20 radioimmunoconjugates (RIT) 131I-tositumomab and 90Y-ibritumomab-tiuxetan. The later clinical success of the first approved antibody-drug conjugate (ADC) for the treatment of lymphomas, anti-CD30 brentuximab vedotin, paved the path for the preclinical development and clinical testing of several other ADCs, including polatuzumab vedotin and loncastuximab tesirine. Other modalities of TDD are based on new formulations of "old" cytostatic agents and their passive trapping in the lymphoma tissue by means of the enhanced permeability and retention (EPR) effect. Currently, the diagnostic and restaging procedures in aggressive lymphomas a2022-01-01T00:00:00Z2022 Jan2025-04-05T00:33:41.352Z2024-11-13T11:04:50.318ZS-EPMC88337833515889410.3390/cancers14030626